S&P 500   3,925.43
DOW   31,961.86
QQQ   324.13
S&P 500   3,925.43
DOW   31,961.86
QQQ   324.13
S&P 500   3,925.43
DOW   31,961.86
QQQ   324.13
S&P 500   3,925.43
DOW   31,961.86
QQQ   324.13
Log in
NYSE:NVO

Novo Nordisk A/S Stock Forecast, Price & News

$72.19
+0.51 (+0.71 %)
(As of 02/24/2021 12:00 AM ET)
Add
Compare
Today's Range
$71.66
Now: $72.19
$72.69
50-Day Range
$68.93
MA: $72.09
$75.82
52-Week Range
$49.24
Now: $72.19
$75.86
Volume864,196 shs
Average Volume1.15 million shs
Market Capitalization$169.99 billion
P/E Ratio27.14
Dividend Yield1.03%
Beta0.46
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharmaceuticals. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company has a strategic alliance with Evotec AG to discover and develop small molecule therapies to treat patients suffering from diabetes, obesity, and co-morbidities, as well as has a research collaboration with Kallyope Inc. Novo Nordisk A/S also has collaboration agreements with Lund University to develop stem cell-derived treatment for Parkinson's diseases; Staten Biotechnology B.V. to develop novel therapeutics for the treatment of dyslipidaemia; Medtronic plc to develop integrated digital solutions for people with diabetes; and bluebird bio, Inc. to develop in vivo genome editing treatments for genetic diseases, as well as research collaboration and license agreement with Procyon Technologies LLC to develop an implantable cell encapsulation device to be used in a novel therapy for Type 1 diabetes. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Novo Nordisk A/S logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone45-4444-8888
Employees44,326
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$18.30 billion
Cash Flow$2.88 per share
Book Value$3.65 per share

Profitability

Net Income$5.84 billion

Miscellaneous

Outstanding Shares2,354,800,000
Market Cap$169.99 billion
Next Earnings Date5/5/2021 (Estimated)
OptionableOptionable

MarketRank

Overall MarketRank

1.34 out of 5 stars

Medical Sector

643rd out of 1,958 stocks

Pharmaceutical Preparations Industry

326th out of 772 stocks

Analyst Opinion: 1.1Community Rank: 2.1Dividend Strength: 1.7Insider Behavior: 0.0Valuation: 1.9 5 -4 -3 -2 -1 -
$72.19
+0.51 (+0.71 %)
(As of 02/24/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive NVO News and Ratings via Email

Sign-up to receive the latest news and ratings for NVO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Novo Nordisk A/S (NYSE:NVO) Frequently Asked Questions

Is Novo Nordisk A/S a buy right now?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novo Nordisk A/S in the last year. There are currently 2 sell ratings, 5 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Novo Nordisk A/S stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVO, but not buy additional shares or sell existing shares.
View analyst ratings for Novo Nordisk A/S
or view top-rated stocks.

What stocks does MarketBeat like better than Novo Nordisk A/S?

Wall Street analysts have given Novo Nordisk A/S a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Novo Nordisk A/S wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Novo Nordisk A/S?

Novo Nordisk A/S saw a increase in short interest in January. As of January 15th, there was short interest totaling 4,910,000 shares, an increase of 21.2% from the December 31st total of 4,050,000 shares. Based on an average trading volume of 1,130,000 shares, the short-interest ratio is presently 4.3 days. Approximately 0.3% of the shares of the stock are sold short.
View Novo Nordisk A/S's Short Interest
.

When is Novo Nordisk A/S's next earnings date?

Novo Nordisk A/S is scheduled to release its next quarterly earnings announcement on Wednesday, May 5th 2021.
View our earnings forecast for Novo Nordisk A/S
.

How were Novo Nordisk A/S's earnings last quarter?

Novo Nordisk A/S (NYSE:NVO) issued its quarterly earnings results on Tuesday, February, 2nd. The company reported $4.01 earnings per share for the quarter, beating analysts' consensus estimates of $0.60 by $3.41. Novo Nordisk A/S had a trailing twelve-month return on equity of 71.46% and a net margin of 32.65%.
View Novo Nordisk A/S's earnings history
.

How has Novo Nordisk A/S's stock price been impacted by COVID-19 (Coronavirus)?

Novo Nordisk A/S's stock was trading at $57.89 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, NVO shares have increased by 24.7% and is now trading at $72.19.
View which stocks have been most impacted by COVID-19
.

How often does Novo Nordisk A/S pay dividends? What is the dividend yield for Novo Nordisk A/S?

Novo Nordisk A/S announced a semi-annual dividend on Tuesday, February 23rd. Stockholders of record on Monday, March 29th will be given a dividend of $0.9494 per share on Wednesday, April 7th. This represents a yield of 1.3%. The ex-dividend date of this dividend is Friday, March 26th. This is a positive change from Novo Nordisk A/S's previous semi-annual dividend of $0.78.
View Novo Nordisk A/S's dividend history
.

Is Novo Nordisk A/S a good dividend stock?

Novo Nordisk A/S pays an annual dividend of $0.74 per share and currently has a dividend yield of 1.03%. The dividend payout ratio of Novo Nordisk A/S is 30.08%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Novo Nordisk A/S will have a dividend payout ratio of 25.00% next year. This indicates that Novo Nordisk A/S will be able to sustain or increase its dividend.
View Novo Nordisk A/S's dividend history.

What guidance has Novo Nordisk A/S issued on next quarter's earnings?

Novo Nordisk A/S issued an update on its FY 2021 Pre-Market earnings guidance on Wednesday, February, 3rd. The company provided EPS guidance of for the period. The company issued revenue guidance of $21.354-22.167 billion, compared to the consensus revenue estimate of $21.76 billion.

What price target have analysts set for NVO?

10 brokers have issued 12 month price objectives for Novo Nordisk A/S's shares. Their forecasts range from $72.00 to $72.00. On average, they anticipate Novo Nordisk A/S's share price to reach $72.00 in the next year. This suggests that the stock has a possible downside of 0.3%.
View analysts' price targets for Novo Nordisk A/S
or view top-rated stocks among Wall Street analysts.

Who are Novo Nordisk A/S's key executives?

Novo Nordisk A/S's management team includes the following people:
  • Mr. Lars Fruergaard Jørgensen, Pres, CEO & Member of Management Board (Age 55)
  • Mr. Karsten Munk Knudsen, Exec. VP, CFO & Member of the Management Board (Age 50)
  • Dr. Mads Krogsgaard Thomsen, Exec. VP, Chief Scientific Officer, Head of R&D and Member of the Management Board (Age 61)
  • Mr. Henrik Ehlers Wulff, Exec. VP, Head of Product Supply, Quality & IT and Member of the Management Board (Age 51)
  • Ms. Camilla Sylvest, Exec. VP, Head of Commercial Strategy & Corp. Affairs and Member of the Management Board (Age 49)
  • Ms. Monique Carter, Exec. VP, Head of People & Organisation and Member of Management Board (Age 48)
  • Mr. Maziar Mike Doustdar, Exec. VP, Head of International Operations & Member of the Management Board (Age 51)
  • Mr. Douglas J. Langa, Exec. VP, Head of North America Operations & Member of Management Board (Age 55)
  • Mr. Ludovic Helfgott, Exec. VP, Head of Biopharm & Member of Management Board (Age 47)
  • Mr. Peter Hugreffe Ankersen, Head of Investor Relations & Corp. VP

What is Lars Fruergaard Jørgensen's approval rating as Novo Nordisk A/S's CEO?

372 employees have rated Novo Nordisk A/S CEO Lars Fruergaard Jørgensen on Glassdoor.com. Lars Fruergaard Jørgensen has an approval rating of 92% among Novo Nordisk A/S's employees. This puts Lars Fruergaard Jørgensen in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Novo Nordisk A/S's key competitors?

What other stocks do shareholders of Novo Nordisk A/S own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Novo Nordisk A/S investors own include Gilead Sciences (GILD), AbbVie (ABBV), Pfizer (PFE), NVIDIA (NVDA), Johnson & Johnson (JNJ), Alibaba Group (BABA), QUALCOMM (QCOM), Cisco Systems (CSCO), AT&T (T) and Abbott Laboratories (ABT).

What is Novo Nordisk A/S's stock symbol?

Novo Nordisk A/S trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVO."

Who are Novo Nordisk A/S's major shareholders?

Novo Nordisk A/S's stock is owned by many different retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (1.14%), Fisher Asset Management LLC (0.67%), Folketrygdfondet (0.24%), Fayez Sarofim & Co (0.21%), Everett Harris & Co. CA (0.14%) and Clearbridge Investments LLC (0.11%).
View institutional ownership trends for Novo Nordisk A/S
.

Which major investors are selling Novo Nordisk A/S stock?

NVO stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Eaton Vance Management, Jennison Associates LLC, Credit Suisse AG, BlackRock Inc., Alliancebernstein L.P., Calamos Advisors LLC, and Exencial Wealth Advisors LLC.
View insider buying and selling activity for Novo Nordisk A/S
or view top insider-selling stocks.

Which major investors are buying Novo Nordisk A/S stock?

NVO stock was acquired by a variety of institutional investors in the last quarter, including Morgan Stanley, Amundi Pioneer Asset Management Inc., Clearbridge Investments LLC, Folketrygdfondet, Fisher Asset Management LLC, Aperio Group LLC, Creative Planning, and Penbrook Management LLC.
View insider buying and selling activity for Novo Nordisk A/S
or or view top insider-buying stocks.

How do I buy shares of Novo Nordisk A/S?

Shares of NVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Novo Nordisk A/S's stock price today?

One share of NVO stock can currently be purchased for approximately $72.19.

How much money does Novo Nordisk A/S make?

Novo Nordisk A/S has a market capitalization of $169.99 billion and generates $18.30 billion in revenue each year. The company earns $5.84 billion in net income (profit) each year or $2.46 on an earnings per share basis.

How many employees does Novo Nordisk A/S have?

Novo Nordisk A/S employs 44,326 workers across the globe.

What is Novo Nordisk A/S's official website?

The official website for Novo Nordisk A/S is www.novonordisk.com.

Where are Novo Nordisk A/S's headquarters?

Novo Nordisk A/S is headquartered at Novo Alle, Bagsvaerd G7, 2880.

How can I contact Novo Nordisk A/S?

Novo Nordisk A/S's mailing address is Novo Alle, Bagsvaerd G7, 2880. The company can be reached via phone at 45-4444-8888 or via email at [email protected]


This page was last updated on 2/25/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.